# Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD

> **NCT03051256** · PHASE2 · COMPLETED · sponsor: **Relmada Therapeutics, Inc.** · enrollment: 62 (actual)

## Conditions studied

- Depressive Disorder, Major
- Depressive Disorder, Treatment-Resistant

## Interventions

- **DRUG:** REL-1017
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03051256
- **Lead sponsor:** Relmada Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-11
- **Primary completion:** 2019-07-30
- **Final completion:** 2019-09-30
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2023-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03051256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03051256, "Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03051256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*